An interventional study of Fastigial Nucleus Stimulation and Standard treatment in Coronary Disease, sponsored by Affiliated Hospital of North Sichuan Medical College. Status unknown at 1 site in China. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2019-10-10.
Sponsored by Affiliated Hospital of North Sichuan Medical College · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 224 studies in Coronary Disease with a site in China — 69 open to participants now, 78 under way, 3 of them phase 3. Coronary Disease · China.
Among the 224 studies in Coronary Disease with a site in China, this one is the 76th largest by planned enrollment of the 142 interventional ones that give a count, is one of 10 that started in 2019, is one of 87 with no phase, and was the 108th registered.
1,522 studies on the registry are indexed under Coronary Disease; 168 are open to participants now.
Browse Coronary Disease studies →69 of the 224 studies in Coronary Disease with a site in China are open now. Recruiting first, the newest first:
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Gan Lijun · Sites in China
Ages 18+
Xia Liang · Sites in China
Ages 50–75
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 105 Coronary Disease studies recruiting now, 63 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
224 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 10 · Phase 4 34
First in 1999; this study’s year is marked. 10 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 160 across 780 interventional studies indexed under Coronary Disease.
Median enrollment 220 across the 142 interventional studies, 1,508 across the 82 observational. Of the 75 that completed or were terminated, 11 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 224 have an industry lead sponsor. The 10 most frequent:
Affiliated Hospital of North Sichuan Medical College is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Affiliated Hospital of North Sichuan Medical College has 1 study filed under Coronary Disease — fewer than ten, so there is no comparison to draw.
22 of the studies in Coronary Disease with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05997693Phase 3Weill Medical College of Cornell UniversityOne-Month DAPT in CABG Patients | 2027-01 |
| NCT06472908Phase 3Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyEfficacy and Safety of Colchicine After PCI | 2027-06-30 |
| NCT07259278China National Center for Cardiovascular DiseasesIntelligent Management Platform for Guiding Exercise Rehabilitation in Coronary Heart Disease Patients | 2026-11-30 |
| NCT07841275China Academy of Chinese Medical SciencesReal-World Effectiveness and Costs of Yiqi Fumai Lyophilized Injection in Coronary Heart Disease-Related Chronic Heart Failure | 2026-12 |
| NCT05397392Nanjing First Hospital, Nanjing Medical UniversityResearch on Optimal Diagnosis and Treatment of Cardiorenal Syndrome | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 224 studies in Coronary Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To observe the effects of fastigial nucleus stimulation on serum inflammation, oxidative stress related factors, cardiac autonomic function and prognosis in patients with coronary heart disease
In recent years, with the improvement of the material living standards of the investigators residents and the change of working lifestyle, the prevalence and mortality of coronary heart disease (CHD) in urban and rural residents in China have increased year by year. According to statistics, the number of patients with coronary heart disease in China is currently 11 million. Coronary heart disease has become a major health problem in China. At present, it is found that inflammatory reaction and oxidative stress factors are involved in the occurrence and development of coronary heart disease, and their indicators such as heart rate variability are related to the prognosis of coronary heart disease. Fastigial nucleus stimulation (FNS) has been widely used in the treatment of various diseases such as cerebrovascular disease, migraine, and eye diseases. The study found that FNS can reduce inflammatory cytokines and oxidative stress factors in ischemic myocardium and improve heart rate variability in rats with myocardial infarction. The aim of this study was to investigate whether FNS can improve the aforementioned indicators and clinical outcomes in patients with coronary heart disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
standard medication:Refer to the "Guidelines for Rational Use of Coronary Heart Diseases"
Drug: Standard treatment
1. fastigial nucleus stimulation:Use fastigial nucleus stimulation therapy device (Shanghai Renhe Medical Equipment Co., Ltd. CVFT series), each stimulation for 30 min, once a day, each patient treatment for about 20 days. 2. standard medication:Refer to the "Guidelines for Rational Use of Coronary Heart Diseases"
Device: Fastigial Nucleus Stimulation · Drug: Standard treatment
Select mode 3, frequency 136, intensity below 90, ratio 1.0-2.0, based on the patient's no discomfort. The main pole is attached to the bilateral mastoid, and the auxiliary pole is attached to the bilateral internal cave. Non-invasive introduction of bio-electricity into the cerebellar nucleus for stimulation
Also known as: Standard treatment
Refer to the "Guidelines for Rational Use of Coronary Heart Diseases".rational selection of antiplatelet drugs, statins, etc. according to the patient's condition
Observe the changes of serum IL-6 after treatment.
Observe the changes of serum IL-6 levels(pg/ml)after treatment in the two groups of patients.
Time frame: baseline,1month
Observe the changes of serum hs-CRP after treatment.
Observe the changes of serum hs-CRP levels(mg/l)after treatment in the two groups of patients.
Time frame: baseline,1month
Observe the changes of serum TNF-α after treatment.
Observe the changes of serum TNF-α levels(pg/ml)after treatment in the two groups of patients.
Time frame: baseline,1month
Observe the changes of serum Lp-PLA2 after treatment.
Observe the changes of serum Lp-PLA2 levels(ng/ml)after treatment in the two groups of patients.
Time frame: baseline,1month
Observe the changes of serum SOD(Superoxide dismutase) after treatment.
Observe the changes of serum SOD levels(ng/ml)after treatment in the two groups of patients.
Time frame: baseline,1month
Observe the changes of serum GPX(Glutathione peroxidase) after treatment.
Observe the changes of serum GPX levels(ng/ml)after treatment in the two groups of patients.
Time frame: baseline,1month
Observe the changes of serum MDA(Malondialdehyde) after treatment.
Observe the changes of serum MDA levels(nmol/ml)after treatment in the two groups of patients.
Time frame: baseline,1month
Observe the changes of serum AOPP(Advanced oxidation protein product) after treatment.
Observe the changes of serum AOPP levels(umol/l)after treatment in the two groups of patients.
Time frame: baseline,1month
Observe the changes of SDNN(Standard Deviation of the NN intervals) after treatment.
Observe the changes of SDNN(ms)after treatment in the two groups of patients.
Time frame: baseline,1month
Observe the changes of SDANN(Standard Deviation of mean NN intervals in 5-minute recordings) after treatment.
Observe the changes of SDANN(ms)after treatment in the two groups of patients.
Time frame: baseline,1month
Observe the changes of SDNN In(Average of the standard deviation of the NN interval every 5 minutes) after treatment.
Observe the changes of SDNN In(ms)after treatment in the two groups of patients.
Time frame: baseline,1month
Observe the changes of rMSSD(square root of the mean squared differences of successive NN intervals) after treatment.
Observe the changes of rMSSD(ms)after treatment in the two groups of patients.
Time frame: baseline,1month
Observe the changes of pNN50(Percentage of the difference between adjacent RR intervals >50ms ) after treatment.
Observe the changes of pNN50(%)after treatment in the two groups of patients.
Time frame: baseline,1month
Follow-up rate of major cardiovascular events
The improvement of symptoms and the in-stent restenosis, myocardial infarction, readmission due to heart failure, and mortality were observed in the two groups after 12 months of discharge.
Time frame: 12months
Plan to share: Yes — De-identified individual participant data for all primary and secondary outcome measures will be made available
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Data will be available within 6months of study completion
Access criteria: Data access requests will be reviewed by an external independent Reviwe Panel.Requestors will be required to sign a Data Access Agreement
Data sharing details ↗ · bethesda.org
No publications or documents are linked to this record.
Started Jan 2019 (actual). Primary completion is estimated for Jan 2021, 24 months after the start.
Of 178 non-industry interventional studies with no phase under Coronary Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 24 months is close to that.
Counting every sponsor, half of 200 studies reached it within 25 months; a quarter within 14 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Affiliated Hospital of North Sichuan Medical College